for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

85.16USD

Change

1.19(+1.42%)

Volume

12,096,016

Today's Range

84.35

 - 

85.87

52 Week Range

66.10

 - 

87.35

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
83.97
Open
84.62
Volume
12,096,016
3M AVG Volume
203.38
Today's High
85.87
Today's Low
84.35
52 Week High
87.35
52 Week Low
66.10
Shares Out (MIL)
2,560.37
Market Cap (MIL)
214,994.70
Forward P/E
16.88
Dividend (Yield %)
2.62

Next Event

Merck & Co Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Merck’s PIFELTRO And DELSTRIGO Receive US FDA Approval For Use In Appropriate Adults Living With HIV-1 Who Are Virologically Suppressed

FDA Approves KEYTRUDA plus LENVIMA Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

U.S. FDA Says Announcing Project Orbis, An Initiative Of The FDA Oncology Center Of Excellence

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, President, Chief Executive Officer

Robert M. Davis

Executive Vice President, Global Services, Chief Financial Officer

Steven C. Mizell

Executive Vice President, Chief Human Resources Officer, Human Resources

Jim Scholefield

Executive Vice President, Chief Information and Digital Officer

Michael T. Nally

Executive Vice President, Chief Marketing Officer

Key Stats

1.71 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

39.8K

2017

40.1K

2018

42.3K

2019(E)

45.9K
EPS (USD)

2016

3.780

2017

3.980

2018

4.340

2019(E)

4.919
Price To Earnings (TTM)
22.64
Price To Sales (TTM)
4.85
Price To Book (MRQ)
7.80
Price To Cash Flow (TTM)
15.78
Total Debt To Equity (MRQ)
96.21
LT Debt To Equity (MRQ)
82.40
Return on Investment (TTM)
14.71
Return on Equity (TTM)
11.36

Latest News

Reuters asks judge to release secret Propecia documents

Reuters asked a U.S. judge on Thursday to unseal documents filed in court regarding potential risks associated with Propecia, Merck & Co's popular baldness drug.

FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

HHS to provide $23 million to Merck for Ebola vaccine production

The U.S. Department of Health and Human Services (HHS) said on Wednesday it will fund the manufacturing of Merck & Co Inc's investigational Ebola vaccine called V920, in response to the outbreak of the deadly virus in the Democratic Republic of the Congo (DRC).

Breakingviews - The Exchange: Nile Rodgers and Merck Mercuriadis

How much is a song worth? Two people who should know are the Chic founder and his manager, who have started a company to buy some of the world’s most famous back catalogues. They explain how music investing works and why many songwriters are miffed with Spotify.

UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute

British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat

Merck & Co Inc <MRK.N> reported better-than-expected second-quarter results on Tuesday and raised its full-year earnings forecast on strong demand for its blockbuster cancer immunotherapy Keytruda and vaccines.

Merck profit surges on strong sales of Keytruda, vaccines

U.S. drugmaker Merck & Co Inc reported a 56.4% rise in second-quarter profit on Tuesday, boosted by strong demand for its Keytruda immunotherapy, the dominant treatment for lung cancer, as well as higher sales of its vaccines.

Merck's treatment for urinary, abdominal infections gets FDA approval

The U.S. Food and Drug Administration has approved Merck & Co Inc's combination treatment for complicated forms of urinary tract and abdominal infections, the drugmaker said on Wednesday.

Merck's treatment for urinary, abdominal infections gets FDA approval

The U.S. Food and Drug Administration has approved Merck & Co Inc's combination treatment for complicated forms of urinary tract and abdominal infections, the drugmaker said on Wednesday.

U.S. judge strikes down Trump administration rule requiring drug prices in TV ads

A federal judge on Monday dealt a blow to the Trump administration by striking down a new rule that would have forced pharmaceutical companies to include the wholesale prices of their drugs in television advertising.

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted.

Walmart, Merck in blockchain collaboration with FDA

IBM Corp, Merck & Co, KPMG and Walmart Inc said on Thursday they will be a part of U.S. Food and Drug Administration's pilot program that will explore using blockchain to identify, track and trace prescription drugs.

Merck's Keytruda wins FDA approval to treat head and neck cancer

Merck & Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer.

Merck's Keytruda wins FDA approval to treat head and neck cancer

Merck & Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer.

Merck to buy Tilos Therapeutics for up to $773 million

Drugmaker Merck & Co Inc said on Monday it agreed to buy privately held Tilos Therapeutics for up to $773 million, bolstering its pipeline of drugs to treat cancer and autoimmune diseases.

Merck wins U.S. FDA approval for expanded use of antibiotic

The U.S. Food and Drug Administration said https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia on Monday it approved expanded use of Merck & Co Inc's antibiotic to treat hospital-acquired...

Merck wins U.S. FDA approval for expanded use of antibiotic

The U.S. Food and Drug Administration on Monday approved expanded use of Merck & Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Merck buys Peloton to expand its kidney cancer treatment portfolio

U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company's lead kidney cancer drug candidate.

Merck to buy cancer drug developer Peloton for $1.05 bln in cash

Merck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 billion in cash to gain access to the privately held company's renal cancer drug candidate.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up